How to Apply Mirvaso: Treat Rosacea Now

Redheads, do you cover up your facial redness with loads of makeup and cover up? Many fair-skinned people, suffer from rosacea. There is no need to suffer from red skin. Get ready for real redness relief. The product is called MIRVASO® (brimonidine) topical gel, 0.33%*, and it comes in the form of a topical gel. It is the first and only FDA-approved medication developed and indicated to treat persistent facial redness of rosacea.

Redheads suffering from rosacea will love this product because MIRVASO doesn’t cover up the red; it treats it. In clinical studies with MIRVASO, rosacea facial redness was reduced for up to 12 hours.

HOW TO APPLY:

1. Apply a pea-sized amount of MIRVASO to your forehead, chin, nose and each cheek, 1 time each day.

2. Using your fingertips, spread the gel smoothly and evenly in a thin layer over your face. Make sure to avoid contact with your eyes and lips. Do not apply MIRVASO to irritated skin or open wounds.

3. Wash your hands immediately after application.

https://www.youtube.com/watch?v=msgjSR9013U

You may notice that the redness may greatly diminish to allow more of your beautiful skin to shine through! Break up with your makeup, redheads! Enter for a chance to win a trip to the Emmy’s below.

You can show the world how much you love your new skin. Rock it like a Redhead!

 

Important Safety Information

Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children.

Not for oral, ophthalmic, or intravaginal use. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

Photo Credit